<DOC>
	<DOCNO>NCT02901184</DOCNO>
	<brief_summary>Heart failure preserve ejection fraction ( HFPEF ) common deadly without therapy . Inconclusive study TOPCAT ( Treatment Preserved Cardiac Function Heart Failure With Aldosterone Antagonist ) suggest spironolactone may effective HFPEF , generic study industry . SPIRRIT unique Registry-Randomized Clinical Trial ( RRCT ) test hypothesis spironolactone reduce all-cause mortality HFPEF summarize PICO ( Patient Intervention Comparison Outcome ) follow : Population : HFPEF patient Swedish Heart Failure Registry . HFPEF define symptoms/signs HF , elevate NTproBNP ( B-type Natriuretic Peptide ; N-terminal pro b-type Natriuretic Peptide ) EF &gt; =40 % . Intervention control : Randomized 1:1 intervention : spironolactone + usual care vs. control : usual care alone . Outcome : Primary outcome all-cause mortality . Secondary outcome include hospitalization various cause , adverse event treatment adherence . Outcomes obtain automatically link Population , Patient Drug Dispensed Registries . The trial event-driven enrollment 3 year study duration 5 year . Based actual patient meet eligibility 2008-2010 , control death rate 0.141 / year . Based TOPCAT accounting dropout , investigator conservatively assume hazard ratio 0.85 , clinically meaningful 15 % reduction death , yield require number event 1208 sample size 3335 , conservatively rounded 3500 . A detailed feasibility assessment show &gt; 8197 eligible patient meet require enrollment 3500 .</brief_summary>
	<brief_title>Spironolactone Initiation Registry Randomized Interventional Trial Heart Failure With Preserved Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Written inform consent Age ≥50 year Stable heart failure define symptom sign heart failure judge local Investigator Left ventricular ejection fraction ( LVEF ) ≥40 % record last 12 month ( stratify max 2/3rd either 4049 % ≥50 % group ) NTproBNP ( Nterminal prohormone brain natriuretic peptide ) &gt; 300 ng/L sinus rhythm &gt; 750 ng/L atrial fibrillation outpatient prior hospital discharge Previously enrol study Known Ejection Fraction &lt; 40 % ever Current absolute indication contraindication MRA ( mineral receptor antagonist ) judgement Investigator Any condition heart failure life expectancy &lt; 3 year Known chronic liver disease Probable alternative explanation symptom : Known primary cardiomyopathy ( hypertrophic , constrictive , restrictive , infiltrative , congenital ) Primary hemodynamically significant valve disease Rightsided HF due leftsided HF Significant chronic pulmonary disease define Investigator requirement home O2 oral steroid , Hemoglobin &lt; 10 g/dL ( 100 g/L ) BMI ( body mass index ) &gt; 40 Heart rate &gt; 105 bpm Any condition judge Investigator responsible symptom and/or sign Heart transplant LVAD ( leave ventricular assist device ) recipient Systolic blood pressure &lt; 90 &gt; 160 K ( potassium ) &gt; 5.0 mmol/L eGFR ( estimate glomerular filtration rate ) MDRD ( Modification Diet Renal Disease ) &lt; 30 ml/min/1.73m2 creatinine &gt; 2.5 mg/dL ( 221 µmol/L ) Current lithium use Actual potential pregnancy Participation another clinical trial treatment HF study Any condition opinion Investigator may interfere adherence trial protocol</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>